Intrabodies

Tat-transactivation Anti-hCyclinTl intrabodies tdTat Transdominant HIV Tat protein scFV to Tat Tar decoy HIV-1 Bahner et al. 1996 Bevec et al. 1996 Duan et al. 1994 Malim et al. 1989 Malim et al. 1988 Reddy et al. 1999... 

Bai J, Rossi J, Akkina R (2001) Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy. AIDS Res Hum Retroviruses 17 385-399 Bai J, Sui J, Zhu RY, TaUarico AS, Gennari F, Zhang D, Marasco WA (2003) Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCychnTl intrabodies. J Biol Chem 278 1433-1442... 

RAJPAL, A., TURI, T.G., Intracellular stability of anti-caspase-3 intrabodies determines efficacy in re-targeting antigen, J. Biol. Chem., 2001, 2001, 33139-33146. 

ZHU, Q ZENG, C HUHALOV, A., YAO, J., TURI, T.G., DANLEY, D., HYNES, T CONG, Y., DIMATTIA, D., KENNEDY, S., DAUMY, G., SCHAEFFER, E., MARASCO, W.A., HUSTON, J.S., Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7, J. Immunol. Methods, 1999, 231, 207-222. 

One very new and powerful area of research is that of monoclonal intrabodies (also called intracellular antibodies), which represent a new class of targeting molecules with potential use in gene therapy. Due to their totally different targets, namely inside a cell, and thus different effector functions, they may have a high potential in the treatment of human diseases [6]. 

With the development of special types of mAbs such as monoclonal intrabodies, antibody fragments with considerably lower molecular mass (see Section 3.4.2.5), enhanced tissue penetration is expected. Studies conducted in vitro or in animals revealed that small-sized antibody fragments can penetrate tissues more easily, might potentially cross the blood-brain barrier, and can be delivered locally to the... 

Rondon, I.J., and W.A. Marasco. 1997. Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. 

Messer A, McLear J (2006) The therapeutic potential of intrabodies in neurologic disorders Focus on Huntington and Parkinson diseases. BioDrugs 20 327-333. 

Miller TW, Messer A (2005) Intrabody applications in neurological disorders Progress and future prospects. Mol Ther 12 394 01. 

Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A (2005) A human single-chain Ev intrabody preferentially targets amino-terminal Huntingtin s fragments in striatal models of Huntington s disease. Neurobiol Dis 19 47-56. 

Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston IS (2001) Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington s disease. Proc Natl Acad Sci USA 98 4764-4769. 

Cohen, P. A., Intrabodies. Targeting scfv expression to eukaryotic intracellular compartments, Methods Mol. Biol. 2002, 178, 367-378... 

Stocks, M.R., Intrabodies production and promise. Drug Discov. Today, 9, 960, 2004. 

Stocks, M.R., Intrabodies production and promise. Drug Discov. Today, 9, 960, 2004. Leyland-lones, B., Trastuzumab hopes and reahties. Lancet Oncol., 3, 127, 2002. 

Stocks M (2005). Intrabodies as drug discovery tools and therapeutics. Curr. Opin. Chem. Biol. 9(4) 359-365. 

Tanaka T, Rabbitts T H (2003). Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. EmboJ. 22(5) 1025-1035. 

Popkov M, et al (2005). Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. 65(3) 972-981. 

Villani M E, Roggero P, Bitti O, et al. (2005). Immunomodulation of cucumber mosaic virus infection by intrabodies selected in vitro from a stable single-framework phage display library. Plant Mol. Biol. 58 305-316. 

---